QUOTED. 3 August 2020. Danielle Antalffy.
Executive Summary
Diabetes company Dexcom said it expects 2020 revenues to reach $1.85bn driven by new patient adoption of its continuous glucose monitoring (CGM) system including by people with type 2 diabetes. See what SVB Leerink analyst Danielle Antalffy said about Dexcom’s earnings results here.
“Overall, these strong second-quarter results reinforced our view that CGM has become a critical part of many patients’ diabetes management and therefore is likely to be somewhat more resilient in a protracted macroeconomic downturn.” – Danielle Antalffy, analyst, SVB Leerink
Click here for a free trial of Medtech Insight